Aimovig reduces frequency of episodic migraines, five-year data reveals

pharmafile | October 6, 2020 | News story | Manufacturing and Production, Research and Development Aimovig 

Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related peptide (CGRP) antagonist Aimovig (erenumab-aooe) in the treatment of patients with episodic migraine (EM).

The data showed that 383 participants with EM were enrolled in the study after finishing a double-blind placebo-controlled treatment period (DBTP), with 216 completing it. Across these 216 patients, Aimovig generated an average reduction of 5.3 monthly migraine days (MMD) compared to the baseline of 8.7 days observed during the DBTP.

Patients using acute migraine-specific medication (AMSM) such as triptans as treatment saw an average reduction of 4.4 days in AMSM use compared to the DBTP baseline of 6.2 days.

“These important data highlight the sustained efficacy, safety and tolerability profile of Aimovig, and provide crucial information for patients and doctors managing migraine,” explained Dr Messoud Ashina, Professor of Neurology in the Faculty of Health and Medical Sciences at the University of Copenhagen. “The study reinforces the potential of Aimovig to reduce monthly migraine days over the long term for people living with this debilitating, yet underdiagnosed disease. For my patients, more migraine-free days means they’re able to get back to the things that are important to them, like spending more time with family and friends, and being able to go to work.”

Novartis and Amgen confirmed that additional data is incoming, showing “sustained efficacy and no increases in adverse events rates” in EM patients receiving Aimovig after failing between two and four preventative therapies, as well as efficacy across Asia, the Middle East and Africa.

Matt Fellows

Related Content

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, …

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the …


4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year …

Latest content